Jazz Buys Compliance Trouble With FazaClo Acquisition
This article was originally published in The Pink Sheet Daily
Executive Summary
The schizophrenia drug’s previous owner, Azur Pharma, produced a patient brochure that drew a warning letter FDA’s Office of Prescription Drug Promotion.